Patents Assigned to Rimonyx Pharmaceuticals Ltd.
  • Patent number: 7365080
    Abstract: The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: April 29, 2008
    Assignee: Rimonyx Pharmaceuticals Ltd.
    Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel, Regina Zhuk
  • Publication number: 20070191400
    Abstract: The present invention provides pharmaceutical compositions comprising quinazolinecarboxamide derivative, and certain novel quinazolinecarboxamide derivatives capable of inhibiting heparan sulfate-glycosaminoglycan (HS-GAGs) interactions with L-selectin, and useful in the prevention or treatment of various diseases, disorders and conditions mediated by HS-GAGs, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 16, 2007
    Applicant: Rimonyx Pharmaceuticals Ltd.
    Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel, Regina Zhuk
  • Publication number: 20070179137
    Abstract: The present invention relates to a method of screening for small organic molecules that directly inhibit the interaction of glycosaminoglycans (GAGs) with GAG-binding viral proteins (GBVPs), which comprises contacting a GAG with an GBVP in the presence of at least one candidate compound; and measuring the amount of the GAG bound to the GBVP or the amount of the GBVP bound to the GAG, wherein a significant decrease in GAG-GBVP binding as compared to GAG-GBVP binding in the absence of the candidate compound, identifies said compound as inhibitor of the GAG-GBVP interaction. The invention further provides pharmaceutical compositions comprising certain 2-thioxo-thiazolidinone derivatives, particularly useful against virus infections.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 2, 2007
    Applicant: RIMONYX PHARMACEUTICALS LTD.
    Inventors: Paul Gregor, Nicholas Harris, Regina Zhuk
  • Publication number: 20060275214
    Abstract: The present invention relates to methods for screening small organic compounds capable of inhibiting the interactions of glycosaminoglycans with effector cell adhesion molecules. Specifically, the present invention provides a method for screening of small organic compounds, the compounds inhibit the interaction of heparin with L-selectin or P-selectin. The compounds identified by the methods of the invention are useful for treating inflammatory disorders, autoimmune diseases and cancer.
    Type: Application
    Filed: December 30, 2003
    Publication date: December 7, 2006
    Applicant: Rimonyx Pharmaceuticals LTD.
    Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel
  • Publication number: 20060135529
    Abstract: The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.
    Type: Application
    Filed: February 5, 2004
    Publication date: June 22, 2006
    Applicant: Rimonyx Pharmaceuticals Ltd
    Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel, Regina Zhuk